Last reviewed · How we verify
FOLFOXIRI with bevacizumab
FOLFOXIRI with bevacizumab combines three chemotherapy drugs (fluorouracil, oxaliplatin, and irinotecan) with an anti-angiogenic monoclonal antibody to kill colorectal cancer cells and block tumor blood vessel formation.
FOLFOXIRI with bevacizumab combines three chemotherapy drugs (fluorouracil, oxaliplatin, and irinotecan) with an anti-angiogenic monoclonal antibody to kill colorectal cancer cells and block tumor blood vessel formation. Used for Metastatic colorectal cancer (first-line treatment).
At a glance
| Generic name | FOLFOXIRI with bevacizumab |
|---|---|
| Also known as | - bevacizumab, - irinotecan, - oxaliplatin, - leucovorin, - 5-fluorouracil |
| Sponsor | Dutch Colorectal Cancer Group |
| Drug class | Chemotherapy combination with anti-angiogenic monoclonal antibody |
| Target | VEGF (bevacizumab component); topoisomerase I, thymidylate synthase, DNA (FOLFOXIRI components) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFOXIRI is a triplet chemotherapy regimen where fluorouracil and leucovorin inhibit thymidylate synthase, oxaliplatin creates DNA crosslinks, and irinotecan inhibits topoisomerase I. Bevacizumab is a VEGF inhibitor that prevents new blood vessel formation, starving tumors of nutrients and oxygen. Together, they provide multi-modal cytotoxic and anti-angiogenic activity against colorectal cancer.
Approved indications
- Metastatic colorectal cancer (first-line treatment)
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Anemia
- Peripheral neuropathy
- Fatigue
- Mucositis
- Hypertension (bevacizumab-related)
- Bleeding/thrombosis
Key clinical trials
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer (PHASE3)
- Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status (PHASE4)
- A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation (PHASE2)
- FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. (PHASE3)
- Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC (PHASE2)
- FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients (PHASE2)
- Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOLFOXIRI with bevacizumab CI brief — competitive landscape report
- FOLFOXIRI with bevacizumab updates RSS · CI watch RSS
- Dutch Colorectal Cancer Group portfolio CI